Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888939 | 0.85 | CNR1 (0.52) | CNR1 | |
| SCHEMBL4879587 | 0.82 | CNR1 (0.71) | CNR1 | |
| SCHEMBL4890922 | 0.80 | CNR1 (0.62) | CNR1 | |
| SCHEMBL4880580 | 0.79 | CNR1 (0.72) | CNR1 | |
| SCHEMBL4882132 | 0.78 | CNR1 (0.65) | CNR1 | |
| SCHEMBL4885548 | 0.77 | CNR1 (0.70) | CNR1CYP2C9 | |
| SCHEMBL4885513 | 0.76 | CNR1 (0.82) | CNR1 | |
| SCHEMBL4888981 | 0.74 | CNR1 (0.68) | CNR1 | |
| SCHEMBL4887045 | 0.72 | CNR1 (0.79) | CNR1 | |
| SCHEMBL4888334 | 0.72 | CNR1 (0.70) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, HCRTR2 | CNR1 1/4885ALDH1A1 2431/4885CYP1A2 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.